The UK pharmaceutical giant AstraZeneca is doubling down on its commitment to the Chinese drugmaker CSPC Pharmaceutical Group with a new deal worth up to $18.5 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results